Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

NEXT STORY
Advertising, Public Relations, And Related Services Global Market Report 2022
PREV STORY
Aptose to Participate in Two Biotech Events in January 2022
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

 Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and ...

author_avatar
NASDAQ Market News

AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS), allowing U.S. patient enrollment to commence in Phase 3 study

author_avatar
NASDAQ Market News

Annual results for the year ended 31 March 2020

author_avatar
NASDAQ Market News